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OBJECTIVE—Insufﬁcient insulin secretion is a hallmark of type
2 diabetes, and exposure of -cells to elevated lipid levels
(lipotoxicity) contributes to secretory dysfunction. Functional
ablation of protein kinase C ε (PKCε ) has been shown to improve
glucose homeostasis in models of type 2 diabetes and, in
particular, to enhance glucose-stimulated insulin secretion
(GSIS) after lipid exposure. Therefore, we investigated the
lipid-dependent mechanisms responsible for the enhanced GSIS
after inactivation of PKCε .
RESEARCH DESIGN AND METHODS—We cultured islets
isolated from PKCε knockout (PKCε KO) mice in palmitate prior
to measuring GSIS, Ca
2 responses, palmitate esteriﬁcation
products, lipolysis, lipase activity, and gene expression.
RESULTS—The enhanced GSIS could not be explained by
increased expression of another PKC isoform or by alterations in
glucose-stimulated Ca
2 inﬂux. Instead, an upregulation of the
amplifying pathways of GSIS in lipid-cultured PKCε KO -cells
was revealed under conditions in which functional ATP-sensitive
K
 channels were bypassed. Furthermore, we showed in-
creased esteriﬁcation of palmitate into triglyceride pools and
an enhanced rate of lipolysis and triglyceride lipase activity in
PKCε KO islets. Acute treatment with the lipase inhibitor
orlistat blocked the enhancement of GSIS in lipid-cultured
PKCε KO islets, suggesting that a lipolytic product mediates
the enhancement of glucose-ampliﬁed insulin secretion after
PKCε deletion.
CONCLUSIONS—Our ﬁndings demonstrate a mechanistic link
between lipolysis and the amplifying pathways of GSIS in murine
-cells, and they suggest an interaction between PKCε and
lipolysis. These results further highlight the therapeutic potential
of PKCε inhibition to enhance GSIS from the -cell under
conditions of lipid excess. Diabetes 58:1826–1834, 2009
T
ype 2 diabetes is characterized by hyperglycemia
and dyslipidemia, and it results from insufﬁcient
insulin secretion from pancreatic -cells to over-
come the resistance of peripheral tissues to the
actions of insulin. Insulin resistance is driven by genetic
and environmental factors, but it is initially counteracted
by an enlargement of -cell mass and increased insulin
output to maintain normal glucose homeostasis. Subse-
quent loss of -cell mass and function in susceptible
individuals causes impaired glucose homeostasis and pro-
gression to overt type 2 diabetes (1,2). The mechanisms
underlying -cell failure are poorly understood (3–5),
although there is evidence that the -cells of predisposed
individuals are particularly compromised by exposure to
high levels of circulating fatty acids, as occurs during
obesity and insulin resistance (6). Moreover, model sys-
tems in which -cells are chronically exposed to fatty
acids (lipotoxicity) recapitulate both the loss of -cell
mass and many of the insulin secretory defects that are
characteristic of type 2 diabetes (7,8).
Glucose-stimulated insulin secretion (GSIS) consists of
triggering and amplifying pathways (9). Glucose triggers
insulin secretion by generating ATP from oxidative metab-
olism, which closes ATP-sensitive K
 (KATP) channels,
thereby inducing a membrane depolarization that stimu-
lates Ca
2 inﬂux via voltage-dependent Ca
2 channels.
The amplifying pathways allow glucose to potentiate the
secretory response to a given rise in cytosolic Ca
2 in a
depolarized (triggered) -cell (9). There is currently no
consensus on the mechanism(s) coupling glucose metab-
olism to the ampliﬁcation of insulin secretion, although
several have been proposed (10–12). One candidate mech-
anism relates to the regulation by glucose of endogenous
lipid signaling in the -cell (11,12).
The protein kinase C (PKC) superfamily consists of
conventional, novel, and atypical isoforms of serine-threo-
nine protein kinases. The lipid-regulated subgroup of
novel PKCs has been broadly implicated in the develop-
ment of insulin resistance (13). This is particularly true of
the PKCε isoform under conditions of nutrient oversupply
(14–16) and in the livers of human type 2 diabetic subjects
(17). Functional inhibition of PKCε also improves glucose
homeostasis in rodent models of type 2 diabetes (18,19)
and reverses acute lipid-induced hepatic insulin resistance
(20). Unexpectedly, however, we recently found that en-
hancement of GSIS was another major means by which
inhibition of PKCε function improves glucose homeosta-
sis. This enhancement was observed in both dietary and
genetic mouse models of type 2 diabetes and when using
ex vivo models of -cell dysfunction (18). Others have also
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insulin (21). Because the mechanisms by which PKCε
deletion improves GSIS remain unclear, our current aim
was to investigate the potential role of alterations in -cell
lipid metabolism. We demonstrate that after chronic lipid
exposure, PKCε KO islets show a selective increase of the
ampliﬁcation pathways of GSIS. This was associated with
a chronic increase of palmitate tracer incorporation into
triglyceride stores, and it was dependent on an increase in
the subsequent glucose-stimulated hydrolysis of those
stores.
RESEARCH DESIGN AND METHODS
The PKCε KO mouse has global deletion of the Prkce gene, as described
previously (18). Ethical approval for mouse studies was granted by the
Garvan/St. Vincent’s Hospital animal ethics committee. Mice were maintained
on a hybrid 129Sv/C57BL/6 background using PKCε heterozygous (Prkce
/)
breeding pairs; 12-week-old male wild-type (Prkce
/) and PKCε KO
(Prkce
/) littermates were used for experiments. Mice had free access to
water and standard mouse chow and were housed with a 12-h light/dark cycle.
Islet isolation and insulin secretion assays. Islets were isolated as
previously described (22). After pancreatic digestion, islets were puriﬁed
using a Ficoll-paque (GE Healthcare, Chalfont St. Giles, U.K.) gradient before
overnight culture in Dulbecco’s modiﬁed Eagle’s medium with 11 mmol/l
glucose and 10% FCS (Invitrogen, PAISLEY, U.K.). Islets were cultured for a
further 48–72 h (chronic culture) with additional 0.4 mmol/l palmitate coupled
to 0.92% BSA (lipid) or BSA alone prior to study (18).
For insulin secretion assays, islets were preincubated for1hi nKrebs-
Ringer buffer containing HEPES (KRBH) containing 0.1% BSA and 2 mmol/l
glucose. Batches of ﬁve islets were incubated at 37°C for 1 h in 130 l KRBH
containing 0.1% BSA and 2 mmol/l glucose (basal) supplemented with glucose
(20 mmol/l) or other additions, as indicated in the text. For inhibition of
lipolysis, orlistat (Sigma, St. Louis, MO), used at 200 mol/l (unless otherwise
stated), or vehicle (0.52% DMSO) was included in the KRBH throughout the
insulin secretion experiment, but not during chronic culture. Insulin release
was determined by radioimmunoassay (Linco/Millipore, Billerica, MA).
Western blotting. Islet lysis and Western blotting was adapted from previous
protocols (22). Islets were washed and lysed, and protein content was
determined by bicinchoninic acid assay (Pierce/Thermo Scientiﬁc, Rockford,
IL). Then, 25 g protein was resolved on a 7% SDS-PAGE gel (Invitrogen)
before transfer to polyvinylidene diﬂuoride. Membranes were blocked with
milk and probed with the following antibodies for2ha t21°C: anti-PKC (no.
610108; BD Biosciences, San Jose, CA); anti-PKC (no. SC209), anti-PKC (no.
SC213), anti-PKC (no. SC216), and anti–14-3-3 (no. SC1657; Santa Cruz
Biotechnology, Santa Cruz, CA); anti–phospho–acetyl-CoA carboxylase (anti–
phospho-ACC; no. 3661), anti-ACC (no. 3662), anti–phospho–AMP-activated
protein kinase- (anti–phospho-AMPK) Thr172 (no. 2535), and anti-AMPK
(no. 2532; Cell Signaling Technology, Boston, MA); anti–-actin (Sigma); and
anti–hormone-sensitive lipase (anti–Hsl; Abcam, Cambridge, U.K.). Anti–
adipose triglyceride lipase (anti–Atgl) was a gift from M. Watt (Monash
University). After chemiluminescent detection, densitometry was performed
using ImageJ1.38q (National Institutes of Health, Bethesda, MD).
Live cell imaging. Live cell imaging was adapted from Ref. 23, as described
in the METHODS section in the supplementary information, which is available
in an online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0132/DC1.
Lipid tracing, glycerol release, and lipase activity measurements. Lipid
tracing experiments were performed by adding 20 Ci/ml of [U-
14C]palmitate
to the culture media for 48 h with 0.4 mmol/l of unlabeled palmitate coupled
to 0.92% BSA. Lipid extractions, thin-layer chromatography, and liquid scin-
tillation spectrometry was performed as previously described (18,24). For
glycerol release measurements, islets were cultured in palmitate (as above),
and batches of 150 islets were incubated in 50 l KRBH containing 20 mmol/l
glucose for 3.5 h at 37°C. KRBH glycerol content was determined using free
glycerol reagent (Sigma). Triglyceride lipase and cholesteryl-ester hydrolase
activities were assessed using an established protocol (25). Islets were
cultured with palmitate (as above) and acutely stimulated with 20 mmol/l
glucose for 1 h before mechanical homogenization (100 islets/120 l homog-
enization buffer).
RNA isolation and real-time quantitative RT-PCR. RNA extraction and
real-time PCR were performed using the TaqMan system (Applied Biosytems,
Foster City, CA). Detailed methods and probe sets used are described in the
METHODS section in the supplementary information.
Statistics. All statistics were performed using GraphPad Prism5 software
(Graphpad Software, La Jolla, CA) and unpaired Student’s t tests and two-way
ANOVA performed as appropriate. P  0.05 was regarded as signiﬁcant.
RESULTS
Effect of PKC deletion on the expression of other
PKC isoforms. The PKC family controls multiple aspects
of -cell function (26). Therefore, one possible explana-
tion for the increased GSIS from lipid-cultured PKCε KO
islets might be enhanced expression of another PKC
isoform capable of promoting secretion. We therefore
compared the PKC expression proﬁle from islets isolated
from PKCε KO and wild-type mice and cultured for 48 h
with palmitate (chronic lipid culture). Protein levels of
PKC, PKC, and PKC were indistinguishable between
these groups. However, we found slightly increased ex-
pression of PKC in PKCε KO islets after lipid culture, but
this is unlikely to be of functional signiﬁcance because the
expression was not signiﬁcantly altered from the lipid-
cultured wild-type group (Fig. 1A–C). Total DNA and
protein contents of PKCε KO islets were not signiﬁcantly
altered from those of wild-type mice after lipid culture.
Islet DNA content (mean 	 SE) for wild-type islets was
9.1 	 0.26 ng, versus 8.5 	 0.25 ng for PKCε KO (not
signiﬁcant, n 
 10). Islet protein content for wild-type
islets was 320 	 10.3 ng, versus 319 	 9.9 ng for PKCε KO
(not signiﬁcant, n 
 10).
PKCKO islets show enhanced glucose-ampliﬁed
insulin secretion. As shown previously (18), deletion of
PKCε did not alter acute GSIS from islets cultured under
control conditions, but it selectively enhanced this re-
sponse after lipid culture (Fig. 2A). GSIS from islets under
all treatment conditions was inhibited by diazoxide (Fig.
2A), which maintains KATP channels in an open conforma-
tion, preventing membrane depolarization. These results
indicate that the enhanced GSIS in PKCε KO islets was
dependent on normal coupling of glucose metabolism with
depolarization-dependent Ca
2 inﬂux. To measure the
ampliﬁcation pathways, or KATP channel–independent se-
cretion, GSIS assays were performed in the combined
presence of diazoxide and 25 mmol/l KCl (9). The latter
serves as a nonmetabolic depolarizing stimulus to activate
voltage-gated Ca
2 channels and trigger insulin secretion
under conditions in which the glucose-dependent initia-
tion signal is inhibited by diazoxide. The secretory re-
sponse to glucose in this protocol thus represents the
ampliﬁcation pathway (9), which was operative in all
treatment groups (Fig. 2B). Moreover, after lipid culture,
glucose-ampliﬁed insulin secretion was nearly doubled
from PKCε KO islets relative to wild-type islets (Fig. 2B),
whereas no signiﬁcant difference between the two geno-
types was observed under control culture conditions.
These results suggest that an augmentation of the ampli-
fying pathways is a major contributor to the overall
enhancement of GSIS observed in lipid-cultured PKCε KO
islets.
Although quantitatively much smaller than the effect on
GSIS, secretion in response to the depolarizing stimulus
KCl (at basal glucose) was also signiﬁcantly elevated in
PKCε KO versus wild-type islets after lipid culture, but not
under control culture conditions. As expected, this re-
sponse to KCl was induced irrespective of whether KATP
channel closure was blocked with diazoxide (Fig. 2B)o r
not (Fig. 2C). When forskolin was used to activate adenylyl
cyclase and increase cAMP levels, KCl-induced insulin
secretion was enhanced in all treatment groups (Fig. 2C).
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culture and PKCε deletion elicited a signiﬁcantly greater
secretory response than the other conditions.
In addition to its chronic effects, palmitate can also
acutely potentiate GSIS from -cells (27). To test whether
PKCε deletion inﬂuences this process, we examined the
acute effect of palmitate on GSIS from PKCε KO islets
without chronic culture. Addition of palmitate during
static secretion experiments produced equivalent re-
sponses from both PKCε KO and wild-type islets (Fig. 2D),
suggesting that the mechanism underlying the enhanced
GSIS in PKCε KO islets is independent of the potentiation
of GSIS by palmitate.
PKCKO islets have normal intracellular free Ca
2,
NAD(P)H, and ﬂavin adenine dinucleotide levels in
response to high glucose. Although the above results
point strongly to an involvement of PKCε deletion in the
amplifying pathways of GSIS, they do not exclude an effect
on the triggering pathway. To address this more directly,
we measured the increase in intracellular free Ca
2 after
glucose and KCl stimulation. Increases in intracellular free
Ca
2 were equivalent in chronic lipid-cultured PKCε KO
-cells and all other groups tested (Fig. 3A and supplemen-
tary Fig. A1). This argues against alterations in the trigger-
ing pathway, upstream of Ca
2 gating, as being implicated
in the enhanced GSIS we observed in lipid-cultured
PKCε KO islets.
We next measured the redox state of the pyridine
nucleotide NAD(P)H as well as ﬂavin adenine dinucleotide
(FAD
2) as a measure of glucose-stimulated metabolic
ﬂux. The autoﬂuorescent signal captured during these
redox imaging experiments is likely that of mitochondrial
NADH and FAD
2 because of the abundance and concen-
tration of the mitochondrial signal (28). Glucose stimu-
lated both increases in NAD(P)H and decreases in the
FAD
2 signal (indicating increased FADH2), but these
were unaltered by PKCε deletion and/or chronic lipid
culture (Fig. 3B and C). This suggests that normal meta-
bolic ﬂux is maintained under these conditions, and it
indicates that alterations of these hydrogen carriers are
unlikely to be involved in the augmentation of the ampli-
fying pathways of GSIS described above. Under basal
glucose conditions, however, lipid-cultured PKCε KO islets
showed a small signiﬁcant decrease in NAD(P)H levels
and an increase in FAD
2 signal, indicating decreased
FADH2, relative to lipid-cultured wild-type islets (Fig. 3B
and C). Although this suggests that PKCε deletion might
impact basal metabolic ﬂux, we did not pursue this ﬁnding
here, given our focus on GSIS.
Triglyceride levels derived from exogenous palmitate
are elevated in PKCKO islets. Acute incubation of
lipid-pretreated PKCε KO islets with [U-
14C]palmitate had
previously revealed a switch in glucose-regulated lipid
partitioning, favoring lipid esteriﬁcation over oxidation
(18). That approach, however, did not address whether
endogenous lipid pools were chronically altered by
PKCε deletion. We therefore measured incorporation of
[U-
14C]palmitate into neutral lipid pools over 48 h of
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FIG. 1. Expression of PKC isoforms in PKCKO islets. Islets isolated from 12-week-old male mice were cultured for 48 h in the presence of 0.4
mmol/l palmitate coupled to 0.92% BSA (Palm) or BSA alone (Cont) prior to lysis. A: Islet proteins were resolved by SDS-PAGE, and immunoblots
for PKC, PKC, PKC, PKC, and -actin (loading control) were performed. B and C: Densitometry quantiﬁcation of Western blots. Data are
means  SE from a representative experiment with n  4 animals. The experiment was repeated twice from independent islet preparations. *P <
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14C labeling
of diacylglycerols and cholesteryl-esters in PKCε KO and
wild-type islets (Fig. 4A). However, we did observe a
signiﬁcant increase in triglycerides derived from exoge-
nous [U-
14C]palmitate in PKCε KO islets (Fig. 4A). Despite
this, oil red O staining of lipid droplets in chronic lipid-
cultured PKCε KO -cells was indistinguishable from that
of wild-type -cells (data not shown). Expression of the
enzyme diacylglycerol acyltransferase (Dgat1), responsi-
ble for the formation of triglyceride from diacylglycerol,
was unaltered in islets by palmitate culture and/or PKCε
deletion (Fig. 4B), excluding this as a mechanism for the
enhanced triglyceride esteriﬁcation in PKCε KO islets.
One mechanism for the control of lipid partitioning and
deposition of neutral lipid stores is the regulation of ACC
activity by AMPK and the subsequent modulation of
malonyl-CoA production and -oxidation (29). Therefore,
we analyzed phospho-speciﬁc markers of AMPK and ACC
activity by immunoblotting. Phosphorylation of AMPK
(Thr172) was increased subtly yet signiﬁcantly after
chronic lipid culture of islets, but this was equivalent in
both genotypes (Fig. 4C and D), suggesting that alterations
in AMPK activity do not explain the increase in GSIS
observed under these conditions. Chronic lipid culture
has been previously shown to increase AMPK (Thr172)
phosphorylation (30), but in our hands this was not
accompanied by a corresponding change in ACC (Ser79)
phosphorylation (Fig. 4C–E). Although a somewhat sur-
prising ﬁnding, this is still consistent with our overall
conclusion that alterations in the AMPK/ACC axis do not
account for the effects of PKCε deletion on GSIS.
Lipolysis is enhanced in PKCKO islets and is
required to mediate enhanced GSIS after lipid cul-
ture. Mobilization of endogenous neutral lipid stores by
lipolysis has been implicated in GSIS in rat -cells (31,32),
and these processes are glucose regulated in rat and
mouse -cells (33,34). Thus, lipolytic pathways may link
the increased triglyceride formation with the enhanced
lipid-dependent GSIS in PKCε KO islets. Therefore, we
assayed lipolysis as glycerol generation because this me-
tabolite is released from -cells after lipolysis, rather than
being recycled (35). Glucose-stimulated glycerol produc-
tion from PKCε KO islets was signiﬁcantly increased com-
pared with wild-type islets after chronic lipid culture (Fig.
5A), suggesting that enhanced lipolysis might underlie the
augmentation of GSIS observed under these conditions.
To test this more directly, we assessed GSIS in the
presence of the lipase inhibitor orlistat (0.2 mmol/l).
Although without effect on wild-type islets, orlistat com-
pletely blocked the enhancement of GSIS and glucose-
ampliﬁed insulin secretion otherwise observed using
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dependent (supplementary Fig. A2).
Triglyceride lipase activity is enhanced in PKCKO
islets. We next measured glucose-stimulated lipase activ-
ities directly, using homogenates of islets derived from our
different treatment groups. Triglyceride lipolysis was sig-
niﬁcantly enhanced in PKCε KO islets after palmitate cul-
ture and showed a similar, albeit nonsigniﬁcant, increase
after control culture relative to wild-type islets (Fig. 6A).
Cholesteryl-ester hydrolysis was 200-fold lower than that
of triglyceride and was downregulated in control-cultured
PKCε KO islets, relative to wild-type islets, but unaltered by
genotype after palmitate culture (Fig. 6A).
Expression of lipases and associated factors in
PKCKO islets. We used RT-PCR to investigate whether
the enhanced PKCε KO islet triglyceride lipase activity
could simply be explained by increased expression of
lipases or associated genes. Expression of Hsl, Atgl, adi-
ponutrin, and lipoprotein lipase was not increased with
palmitate culture and/or deletion of PKCε (Fig. 6B–D). Atgl
mRNA was slightly decreased by palmitate in PKCε KO
islets (Fig. 6B), but neither mRNA nor protein levels were
altered when compared with wild-type islets, indicating
normal abundance of this lipase (Fig. 6B and D). We
were unable to detect expression of pancreatic triglyc-
eride lipase or the lipid droplet–associated protein
perilipin (data not shown). Expression of /-hydrolase
domain–containing protein 5—a protein known to regu-
late Atgl activity (36)—was unaltered by palmitate culture
and/or PKCε deletion (Fig. 6C). Finally, we measured
translocator protein gene (peripheral benzodiazepine re-
ceptor) mRNA levels because expression of this gene is
known to be induced in some cell types by PKCε activation
(37), and pharmacological activation of translocator pro-
tein causes -cells dysfunction (38). However, expression
of this gene was not altered by palmitate culture and/or
PKCε deletion (Fig. 6C).
DISCUSSION
We have previously shown that functional inhibition of
PKCε prevents glucose intolerance in mice fed a high-fat
diet and improves glycemic control in diabetic db/db mice,
in part because of an enhancement of insulin secretion
(18). Enhanced GSIS from PKCε KO -cells occurred se-
lectively after lipid exposure, in vitro or in vivo, thereby
increasing insulin output under pathophysiological condi-
tions that confer an increased demand for insulin. Because
of the potential therapeutic relevance of these ﬁndings to
the treatment of type 2 diabetes, our current goal was to
further characterize the molecular mechanisms underlying
this phenotype. We ﬁrst excluded the possible upregula-
tion of another -cell PKC isoform capable of promoting
insulin secretion. Although we did ﬁnd a small but signif-
icant increase in PKC—a conventional PKC—in lipid-
cultured PKCε KO islets, this is unlikely to be of functional
relevance because we have previously shown that al-
though conventional PKCs are activated by glucose in the
-cell, they are not required for GSIS (39).
Our current results provide two major advances in
deﬁning the mechanism whereby deletion of PKCε en-
hances GSIS in lipid-cultured islets. First, we have specif-
ically identiﬁed the amplifying pathway as the major site of
action. Importantly, and consistent with the speciﬁcity
reported for overall GSIS (18), the augmentation of the
ampliﬁcation pathway in PKCε KO islets was only observed
after lipid pretreatment. In addition, we have previously
demonstrated an enhancement of both ﬁrst- and second-
phase GSIS after lipid culture of PKCε KO islets (18), which
is still consistent with an enhancement of glucose-ampli-
ﬁed insulin secretion because the amplifying pathways
have been shown to be active during both phases of GSIS
(40). By deﬁnition, the amplifying pathways function inde-
pendently of changes in glucose-regulated intracellular
Ca
2 concentrations (9). Consistent with this, we were
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independent recordings from two independent cell preparations, with
>20 cells monitored per recording. *P < 0.05; **P < 0.01. WT, wild
type.
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2
levels in PKCε KO -cells after lipid culture. However, we
do not exclude an additional effect on the triggering
pathway downstream of Ca
2 inﬂux because we did ﬁnd
slightly enhanced secretion in response to KCl (at basal
glucose concentrations) selectively in lipid-cultured PKCε KO
islets.
The molecular mechanisms underlying the amplifying
pathways are poorly understood and controversial, al-
though glucose-regulated lipid partitioning has been pro-
posed as one coupling mechanism (11,12). Glucose-driven
mitochondrial anaplerotic/cataplerotic pathways increase
cytosolic levels of malonyl-CoA, which inhibits carnitine-
palmitoyl transferase 1, thereby inhibiting -oxidation
and promoting the availability of long-chain acyl-CoA
for esteriﬁcation (41). This partitioning mechanism is a
glucose-regulated signal that mediates, in part, the acute
potentiation of GSIS by exogenous lipids (42). This cou-
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major ﬁnding reported here: enhanced mobilization of
neutral lipid stores contributes to the increased GSIS we
observe. We base this ﬁnding on several pieces of evi-
dence, including, most directly, that orlistat selectively
inhibited the augmented GSIS in lipid-cultured PKCε KO
islets. In contrast to prior studies with rat islets (31,32),
orlistat did not affect GSIS from wild-type mouse islets.
Rat islets differ from mouse (and human) islets in that they
have a more pronounced second phase of secretion (40),
and it is this phase that is most sensitive to inhibition by
orlistat (31). We are unaware of any previous reports of
the effect of orlistat, or other lipase inhibitors, on GSIS
from mouse islets.
The other pieces of evidence for a site of action in lipid
partitioning relate to observed effects of PKCε deletion on
the remodeling of neutral lipid stores. On the one hand,
PKCε KO islets displayed increased incorporation of
[
14C]palmitate into triglyceride during 48-h culture with 11
mmol/l glucose. This extends our previous ﬁnding that
during short-term glucose stimulation, lipid-pretreated
PKCε KO islets were better able than wild-type islets to
partition palmitate away from -oxidation and toward
esteriﬁcation pathways (18). On the other hand, when
assayed directly, glucose-stimulated triglyceride lipase ac-
tivity was increased by PKCε deletion. The simplest expla-
nation for our ﬁndings is that absence of PKCε during
chronic lipid exposure results in enhanced deposition of
triglyceride, which couples with enhanced lipolysis of this
store during acute glucose stimulation and results in
increased liberation of fatty acid in the PKCε KO -cell.
Potential inputs on both the deposition and mobilization of
lipid stores would be consistent with the apparent absence
on any alteration in overall lipid droplet content, and they
imply that turnover of (a possibly unknown) neutral lipid
contributes to the ampliﬁcation of insulin secretion
(31,32,43). How this fatty acid metabolite would act is
unclear, but possibilities include autocrine/paracrine acti-
vation of -cell G-protein–coupled receptors, or effects
exerted intracellularly, via activation of lipid-regulated
protein kinases or via acylation reactions (11,12). A ﬁnal
explanation for the enhanced lipolysis we observed in
PKCε KO islets is that it represents an adaptive response to
minimize the effects of nutrient toxicity after lipid loading
(44). Further studies of the role of PKCε in lipid-cultured
islets should help to resolve these possibilities, and they
might shed further light on the poorly understood mecha-
nisms underlying the amplifying pathways of GSIS.
The molecular targets of PKCε involved in regulating
neutral lipid turnover remain to be identiﬁed, but our
results now narrow the range of options. The ﬁnding that
PKCε deletion affected triglyceride, but not diacylglycerol
or cholesteryl-ester, pools suggests a mode of action
independent of the broad regulation of -oxidation versus
neutral lipid synthesis that is controlled by glucose-stim-
ulated malonyl-CoA levels. This is consistent with the
observation that activation of neither the malonyl-CoA
synthetic enzyme ACC, nor the upstream regulatory kinase
AMPK, was altered when comparing the phosphorylation
status of these proteins from wild-type or PKCε KO islets.
The mechanism underlying the selectivity for deposition
into triglycerides requires further investigation, but is
unlikely to involve an effect of PKCε deletion on general
fatty acid desaturation pathways because these impact on
cholesteryl-ester as well as triglyceride formation in
-cells (24). The individual -cell lipases responsible for
coupling glucose-regulated lipolysis with the ampliﬁcation
of insulin secretion have not been fully established (45).
Hsl is one candidate, although gene knockout studies have
failed to reach a consensus on its role in -cells (33,46,47).
We have shown that the cAMP generator forskolin stimu-
lates enhanced insulin secretion in PKCε KO islets. Be-
cause cAMP also activates lipolysis in -cells (31,48), most
probably via Hsl (49), it is possible that the activity of this
enzyme may be elevated by PKCε deletion. However, the
main Hsl substrates are thought to be diacylglycerols and
cholesteryl-esters (45), so it is unlikely Hsl activity is
responsible for the enhanced triglyceride lipolysis in
PKCε KO islets. Other candidate -cell lipases include Atgl
and adiponutrin; although expression of these lipases was
normal, we cannot rule in or out an upregulation of their
activity in PKCε KO islets. Indeed, the GSIS phenotype in
PKCε KO islets may prove a useful model for further
studying the role of lipases in regulating -cell function.
We have demonstrated that loss of PKCε function repro-
grams the mouse -cell to increase GSIS after lipid expo-
sure, via upregulation of the amplifying pathways of GSIS,
which are dependent on lipolysis. Because loss of -cell
function correlates with poor prognosis during type 2
diabetes, strategies to improve GSIS remain attractive
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FIG. 5. Enhanced lipolysis is required for enhanced secretion in PKCKO islets. Islets isolated from 12-week-old male mice were cultured for
48–72 h in the presence of 0.4 mmol/l palmitate coupled to 0.92% BSA (Palm) or BSA alone (Cont). A: Lipolysis was measured in islets, after
palmitate culture, by detection of glycerol release in response to 20 mmol/l D-glucose (n  7). B: GSIS in palmitate-cultured PKCKO islets in the
presence of the lipase inhibitor orlistat (0.2 mmol/l) or DMSO vehicle control (n  9). C: Glucose-ampliﬁed insulin secretion measured under KATP
channel–independent depolarizing conditions (25 mmol/l KCl and 100 	mol/l diazoxide) using palmitate-cultured PKCKO islets in the presence
of orlistat or DMSO control (n  9). Data are the means  SE. *P < 0.05; **P < 0.01. WT, wild type.
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case for further work on the inhibition of PKCε as a means
of treating type 2 diabetes. Having now demonstrated a
site of action in the amplifying pathways of GSIS, our work
suggests PKCε inhibitors might act as a type of metabolic
incretin, with the added advantage that they appear to
target defective -cells, such as those from db/db mice, or
wild-type islets compromised by prior lipid exposure (18).
Finally, a better understanding of the roles of PKCε in the
-cell could help elucidate the mechanisms whereby
insulin secretion fails during the progression to type 2
diabetes.
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